Related Experiment Video
Updated: Aug 9, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Nephrogenic systemic fibrosis: an update
Shawn E Cowper1, Philip J Boyer
1Yale University, Department of Dermatology, New Haven, CT 06520-8059, USA. shawn.cowper@yale.edu
Abstract:
Nephrogenic systemic fibrosis (NSF), previously known as nephrogenic fibrosing dermopathy, is an emerging systemic fibrosing disorder that develops in the setting of renal insufficiency. Since its recognition in 1997, several case reports of NSF have been published in the rheumatology literature, reflecting the increasing incidence and recognition of this disorder in the United States and abroad. As rheumatology professionals are commonly the first to encounter newly developing cases, it is imperative that they recognize the symptoms and comorbidities of NSF and initiate work-up and treatment. To date, the precise causes of NSF have not been established; however, several promising lines of inquiry have led to a new model of the disorder. This model speculates that circulating fibrocytes of bone marrow origin are aberrantly recruited to the skin and other systemic sites by a process likely triggered or exacerbated by endothelial damage.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Diabetic Nephropathy
Acute Kidney Injury III: Clinical Manifestations
Cirrhosis II: Pathophysiology
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury IV: Diagnostic Studies and Prevention
